Figure 3
Immunologic profiles and tumor protection effects of noncarrier naked and gold particle-coated DNA vaccines. (a) Numbers of E7-specific interferon (IFN)-γ-secreting CD8+ T-cell precursors/3.5 × 105 splenocytes of various DNA vaccinated mice: 1, naive; 2, naked no insert; 3, naked E7; 4, naked CRT; 5, naked CRT/E7; 6, gold particle-coated CRT/E7 (note: mice vaccinated with noncarrier naked or gold particle-coated CRT/E7 DNA generated higher frequencies of E7-specific IFN-γ-secreting CD8+ T-cell precursors when compared with the other groups of mice). (b) Enzyme-linked immunosorbent assay (ELISA) showed E7-specific antibodies in mice vaccinated with various DNA vaccines (note: the titers of anti-E7 antibodies generated by the noncarrier naked or gold particle-coated CRT/E7 DNA showed significantly higher titers of anti-E7 antibodies compared with the other groups). (c) In vivo tumor preventive experiments for tumor-free. (d) In vivo tumor preventive experiments for survival of animals (note: both groups of mice that received noncarrier naked and gold particle-coated CRT/E7 DNA remained tumor-free 60 days, and were still alive 90 days after TC-1 challenge.
